|The full article is available to subscribers||Subscriber Login|
The FDA has approved Incruse Ellipta (GSK), a single-agent inhaler containing the long-acting anticholinergic umeclidinium, for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Umeclidinium was initially approved in combination with the long-acting beta2-adrenergic agonist vilanterol as Anoro Ellipta.1
MAINTENANCE TREATMENT — In patients with moderate to severe COPD, regular treatment with an inhaled long-acting bronchodilator (a beta2-agonist or an anticholinergic) can relieve symptoms, improve lung function, and reduce the frequency of exacerbations. A combination of a beta2-agonist and an anticholinergic can be used for patients inadequately controlled on a single agent.2
CLINICAL STUDIES — In a 12-week, double-blind trial,... more
- Anoro Ellipta: an inhaled umeclidinium/vilanterol combination for COPD. Med Lett Drugs Ther 2014; 56:30.
- Drugs for asthma and COPD. Treat Guidel Med Lett 2013; 11:75.
- R Trivedi et al. Umeclidinium in patients with COPD: a randomised, placebo-controlled study. Eur Respir J 2014; 43:72.
- JF Donohue et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med 2013; 107: 1538.
- JF Donohue et al. Safety and tolerability of once-daily umeclidinium/vilanterol 125/25 mcg and umeclidinium 125 mcg in patients with chronic obstructive pulmonary disease: results from a 52-week, randomized, double-blind, placebo-controlled study. Respir Res 2014; 15:78.